- Home
- CERS vs KMDA Comparison
CERS vs KMDA Comparison
Compare CERS & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERS
- KMDA
- Stock Information
- Founded
- CERS 1991
- KMDA 1990
- Country
- CERS United States
- KMDA Israel
- Employees
- CERS N/A
- KMDA N/A
- Industry
- CERS EDP Services
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- CERS Technology
- KMDA Health Care
- Exchange
- CERS Nasdaq
- KMDA Nasdaq
- Market Cap
- CERS 347.3M
- KMDA 349.1M
- IPO Year
- CERS 1997
- KMDA N/A
- Fundamental
- Price
- CERS $1.30
- KMDA $6.50
- Analyst Decision
- CERS Strong Buy
- KMDA Strong Buy
- Analyst Count
- CERS 2
- KMDA 3
- Target Price
- CERS $3.50
- KMDA $14.67
- AVG Volume (30 Days)
- CERS 1.3M
- KMDA 119.9K
- Earning Date
- CERS 05-01-2025
- KMDA 05-07-2025
- Dividend Yield
- CERS N/A
- KMDA 3.06%
- EPS Growth
- CERS N/A
- KMDA 66.67
- EPS
- CERS N/A
- KMDA 0.25
- Revenue
- CERS $180,270,000.00
- KMDA $160,953,000.00
- Revenue This Year
- CERS $25.57
- KMDA $14.01
- Revenue Next Year
- CERS $10.54
- KMDA $9.24
- P/E Ratio
- CERS N/A
- KMDA $26.51
- Revenue Growth
- CERS 15.29
- KMDA 12.93
- 52 Week Low
- CERS $1.12
- KMDA $4.74
- 52 Week High
- CERS $2.54
- KMDA $9.15
- Technical
- Relative Strength Index (RSI)
- CERS 42.68
- KMDA 50.01
- Support Level
- CERS $1.12
- KMDA $5.78
- Resistance Level
- CERS $1.42
- KMDA $6.21
- Average True Range (ATR)
- CERS 0.11
- KMDA 0.30
- MACD
- CERS 0.01
- KMDA 0.04
- Stochastic Oscillator
- CERS 58.06
- KMDA 75.59
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.